Download David Okrongly

CORPORATE INNOVATION AS
AN ENGINE FOR CHANGE:
Molecular Diagnostics
David Okrongly, Ph.D.
SVP Molecular Diagnostics
Siemens Healthcare
The Era of the Integrated Diagnostics Company is Here
In Vivo Diagnostics (Major Medical Imaging Systems)
X-ray
Computed
Tomography
Healthcare IT
Magnetic
Resonance
Molecular
Imaging
Ultrasound
Preclinical
Imaging
Integrated medical data translated into actionable knowledge
In Vitro Diagnostics (Major Medical Laboratory Systems)
Immunoassay
Molecular
Clinical
Chemistry
Hematology
Urinalysis
Lab
Automation
Blood Gas
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Global health care spending is accelerating
Newwe
science
and
aging
population
further
burden spending
Are
utilizing
the
Diagnostic
Toolbox
well?
15%
1,000
3,835
3,224
2,811
2,211
2,091
1,500
1,984
2,000
1,891
4%
2,589
2,500
2,364
3,000
3,005
3,500
1,800
Global Health Care
4,000
400
4,267
4,500
Source: SG
Cowen
70%
300
200
100
Global Diagnostics
$US Bil
500
0
0
<2%
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Healthcare spent on IVD
Global Health Care
Clinical decision contribution
Global Diagnostics
Source: World Medical Markets Fact Book 2007, SG Cowen, Kalorama, TriMark, Management Estimate
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Highly Active Antiretroviral Drug Therapy
H A AR T
Most common
EI
NEW
NRTI
TX
NRTI
NRTI
INT
INT
PI
NRTI
NNRTI
PI
EI
EI
NNRTI
COMBO
INT
PI
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Cancer Represents a Much More Challenging Picture
Monoclonal Antibodies
Small Molecule Inhibitors
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
How to treat Node Negative Breast Cancer …
NT
Basic Risk Categories of Nodenegative Breast Cancer Patients
without treatment
Current
Treatment
according
to Guidelines
 Molecular markers like Ki67, ErbB2, …
Treatment decisions according
to molecular classification
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Cardiac Risk Assessment
# of MIs
Risk of MI
~33%
100%
90%
80%
70%
7.5%
High risk
~33%
60%
50%
40%
15%
Intermediate risk
~33%
30%
20%
10%
0%
100%
90%
77.5%
80%
Low risk
70%
60%
How???
Molecular
Diagnostics
40%
50%
30%
20%
10%
0%
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
The Era of Molecular Medicine
Molecular Medicine
In Vitro Diagnosis
Systems
Assays
IT Applications
Leverage novel
molecular technologies
for risk assessment,
early detection and
diagnosis of disease
Molecular Imaging
Systems
Knowledge-Driven IT
Biomarkers
Clinical Applications
Visualize and localize
molecular processes
in vivo for diagnosis
and therapy
Integrate medical
information and enable
knowledge-driven clinical
applications
Copyright © 2008 Siemens Healthcare USA, Inc. All rights reserved.
TRANSFORMING PATHOLOGY:
Emerging technology driving practice innovation